Myriad Decision May Invalidate Many Patents

Last year’s Supreme Court decision in Association for Molecular Pathology v. Myriad Genetics, Inc. will have widespread impact on the biotechnology industry, invalidating thousands of patents. Current patent holders who are on the margin do have options, however, as do new applicants. Writing in Today’s General Counsel magazine, Merchant & Gould  IP attorneys describe those options and under what circumstances they might be applicable.